Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cormedix ( (CRMD) ) has issued an announcement.
On June 24, 2025, CorMedix Inc. held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders elected directors to serve until the 2026 meeting, approved the compensation for named executive officers for 2024, and ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (CRMD) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
Cormedix’s overall stock score is influenced by a challenging financial position, marked by ongoing losses and negative cash flows. Despite technical indicators showing potential downward pressure, the recent earnings call provides a positive outlook with record-breaking revenue and strategic growth initiatives. However, valuation concerns and operational challenges remain significant obstacles.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
Average Trading Volume: 1,900,505
Technical Sentiment Signal: Buy
Current Market Cap: $1.12B
See more data about CRMD stock on TipRanks’ Stock Analysis page.